INDIANAPOLIS, Sept. 28, 2015 /PRNewswire/ -- A Phase II study of Eli Lilly and Company's (NYSE: LLY) CYRAMZA® (ramucirumab) in combination with docetaxel met its primary endpoint, demonstrating a statistically significant increase in progression-free survival (PFS) for patients with locally advanced or metastatic urothelial carcinoma who failed prior platinum-based therapy. Bladder cancer accounts for the vast majority of all urothelial carcinoma.
Final results of the Phase II trial were presented at the European Cancer Congress (ECC2015) in Vienna, Austria (Abstract #2508) on September 27. Based on these findings, Lilly recently initiated a Phase III trial called RANGE, which has begun to enroll patients.
Lilly's CYRAMZA® (ramucirumab) Significantly Improves Progression-Free Survival in Phase II Bladder Cancer Trial (NYSE:LLY)
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.